Skip to main content
. 2024 May 16;25(7):801–818. doi: 10.1080/14656566.2024.2356254

Figure 4.

Figure 4.

The journey of evidence for the novel molecules for type 2 diabetes and/or obesity – the ongoing phase 3 and phase 4 clinical trials.

BMI: body mass index, CV: cardiovascular, GLP-1: glucagon-like peptide-1, HbA1c: glycated hemoglobin, MACE: Major Adverse Cardiovascular Event, MI: myocardial infarction, RA: Receptor Agonist, SGLT-2: sodium glucose-cotransporter-2, T2D: type 2 diabetes.